Cic edizioni internazionali
Clinical Cases in mineral and bone metabolism

Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study

Original Article, 195 - 199
doi: 10.11138/ccmbm/2016.13.3.195
Tag this article
Abstract
Enhanced HTML Full text PDF
Introduction. Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. The best defense against osteoporosis in prostate cancer is to identify patients with a high risk for fracture during the first clinical visit, select an effective anti-osteoporosis agent, and advise the patient to change his lifestyle and diet to prevent further bone loss. New agents include denosumab, a human monoclonal antibody that inhibits the RANK ligand (RANKL).
RANKL promotes the formation, activity, and survival of osteoclasts and, thus, supports the breakdown of bone.
Purpose. This is a multicenter, randomized, double-blind prospective study on use of denosumab versus alendronate in the therapy of secondary osteoporosis related to ADT in prostate cancer patients in three European countries (Italy, France, Switzerland).
Patients and methods. In this 24-month observation study we enrolled 234 patients with diagnosis of osteoporosis underwent ADT for prostate cancer. All patients aged ≥55 years and had a dual-energy X-ray absorptiometry (DEXA) T-score <-1.0 (hip or spine, measured within last 2 years) and ≥ 1 fragility fracture. Patients were randomly assigned 1:1 to receive denosumab 60 mg subcutaneously every 6 months or alendronate (70 mg weekly) for 2 years. All patient received supplemental vitamin D (600 IU per day) and supplemental calcium to maintain a calcium intake of 1200 mg per day. Effectiveness of therapy in both groups (denosumab group and alendronate group) was assessed by changes in bone turnover markers (BTMs), Bone Mineral Density (BMD), fracture incidence, Visual Analogue Scale (VAS) score for back pain, and Short Form-8 (SF-8TM) health survey score for healthrelated quality of life (HRQoL). Percent changes from baseline in BTMs and BMD were assessed using the paired t test; a P-value 0.05). Mean changes in BMD at final follow-up differed significantly between two groups. BMD changes at the lumbar spine at 24 months were 5.6% with denosumab vs - 1.1% with alendronate (P<0.001). New vertebral fractures developed in fewer patients in the denosumab group than in the alendronate group during the 24-month period, although this difference was not significant (P=0.10). Back pain significantly (P<0.001) improved from baseline at all time points during the study in both study groups. SF-8 health survey scores significantly improved following treatment with both drugs. Incidence of adverse drug reactions were similar in both groups.
Conclusion. In our study denosumab and alendronate showed similar clinical efficacy in the therapy of ADT-related osteoporosis in men with prostate carcinoma; both drugs provided significant improvements in back pain and general health conditions. Denosumab showed significant increase of BTMs and BMD than alendronate with lower rate of new vertebral fractures.

Vol. XV (No. 2) 2018 May - August

  1. GCMB and PIN1: regulation of parathyroid function on a transcriptional and post-transcriptional level
    Mazzotta C., Cavalli L., Carossino A.M., Brandi M.L.
    doi: 10.11138/ccmbm/2018.15.2.151
  2. Nudging healthier behavior: psychological basis and potential solutions for enhancing adherence
    Gronchi G., Cianferotti L., Parri S., Pampaloni B., Brandi M.L.
    doi: 10.11138/ccmbm/2018.15.2.158
  3. REMS technique: future perspectives in an Academic Hospital
    Caffarelli C., Tomai Pitinca M.D., Francolini V., Alessandri M., Gonnelli S.
    doi: 10.11138/ccmbm/2018.15.2.163
  4. Complex regional pain syndrome: facts on causes, diagnosis and therapy
    de Sire A., Paoletta M., Moretti A., Brandi M.L., Iolascon G.
    doi: 10.11138/ccmbm/2018.15.2.166
  5. The role of alfacalcidol
    Nuti R., Caffarelli C.
    doi: 10.11138/ccmbm/2018.15.2.173
  6. New insights on the role, pathogenesis, and treatment of osteoporosis and bone erosions in rheumatoid arthritis
    Adami G., Viapiana O., Rossini M., Fassio A., Orsolini G., Idolazzi L., Gatti D.
    doi: 10.11138/ccmbm/2018.15.2.177
  7. Dental implants in osteoporotic patients taking oral bisphophonates: a literature review
    Nuti N., Baldini N., D'Elia C., Gabriele G., Gennaro P., Ferrari M.
    doi: 10.11138/ccmbm/2018.15.2.183
  8. Knowledge gap among general practitioners, endocrinologists and orthopedic surgeons regarding atypical lesions and fractures of the femur due to long-term use of bisphosphonates
    Keltz E., Doronov I., Segal E., Keren Y.
    doi: 10.11138/ccmbm/2018.15.2.190
  9. The effect of static compression on the progression of bone healing. An experimental study on rabbits
    Kateros K., Galanakos S.P., Sakellariou V.I., Khaldi L., Karachalios T.
    doi: 10.11138/ccmbm/2018.15.2.196
  10. Synthesis and characterization of etidronic acid (ETD) grafted nano sheets of hydroxyapatite
    Kumar L., Kaushik A.
    doi: 10.11138/ccmbm/2018.15.2.201
  11. Short focus on thyroid function in menopause: impact on bone health
    Capozzi A., Scambia G., Lello S.
    doi: 10.11138/ccmbm/2018.15.2.209
  12. Densitometric evaluation of periprosthetic bone resorption after surgical placement of Accolade I® TMZF® hip stem at 36 months
    Parchi P.D., Ciapini G., Piolanti N., Bonicoli E., Nucci A.M., Mannocci C., Marchetti S., Scaglione M., Maffei S., Lisanti M.
    doi: 10.11138/ccmbm/2018.15.2.211
  13. The use of Poller screws in intramedullary nailing is associated with decreased callus formation
    Cundall-Curry D.J., Lawrence J.E., Fountain D.M., Krkovic M.
    doi: 10.11138/ccmbm/2018.15.2.216
  14. Ilizarov technique, satisfactory outcome with limited resources
    Khan M.S., Di Giacomo L.M., Meccariello L., Bisaccia M., Azzam W., Jatoi A., Rollo G.
    doi: 10.11138/ccmbm/2018.15.2.221
  15. Atypical femoral fractures caused by glucocorticoid and bisphosphonate prolonged therapy in premenopausal women: a case report and literature review
    Franceschet G., Censi S., Cirrone S., Gomiero W., Scaroni C., Camozzi V.
    doi: 10.11138/ccmbm/2018.15.2.227
  16. Incidence of fractures in a cohort of military personnel followed for over two decades
    Kumar KVS H., Patnaik
    doi: 10.11138/ccmbm/2018.15.2.231
  17. Multiple hereditary exostoses: metabolic diagnostics and use of anti-fracture therapy
    Masi L., Brandi M.L.
    doi: 10.11138/ccmbm/2018.15.2.235
  18. Osteolysis around the Fassier-Duval nail and spontaneous femur fracture in a young semi-professional swimmer with Osteogenesis Imperfecta type I: case report and review of literature
    Persiani P., Martini L., Ranaldi F.M., Celli M., Zambrano A., D'Eufemia P., Celli L., Villani C.
    doi: 10.11138/ccmbm/2018.15.2.242
  19. A rare cause of leg pain
    Gaudio A., Rapisarda R., Xourafa A., Zanoli L., Castellino P., Erio Fiore C.
    doi: 10.11138/ccmbm/2018.15.2.246
  20. Non-traumatic myositis ossificans circumscripta in the context of vastus medialis obliquus: a case report
    Vanelli R., Rivellino M.C., Jannelli E., Cuzzocrea F., Pietrobono L., D'Ambrosio G., Mosconi M., Benazzo F.
    doi: 10.11138/ccmbm/2018.15.2.249
  21. Hypophosphatasia in adults: a new manifestation, a new mutation. A case report
    Adami G., Viapiana O., Rossini M., Risoli M., Ganini A., Bertoldo F., Fassio A., Idolazzi L., Antoniazzi F., Gatti D.
    doi: 10.11138/ccmbm/2018.15.2.255
  22. Ewing’s sarcoma of the clavicle: a case report
    Igoumenou V.G., Economopoulou P., Agrogiannis G., Dailiana Z., Mavrogenis A.F.
    doi: 10.11138/ccmbm/2018.15.2.258
  23. Severe osteoporosis with vertebral fracturative progress in liver transplant: a case report
    Bruno R., Casabella A., Palermo A., Nardi A., Molfetta L.
    doi: 10.11138/ccmbm/2018.15.2.262
  24. Monostotic Paget’s disease of the radius: a case report
    Kokkalis Z.T., Kokkineli S., Iliopoulos I.D., Megaloikonomos P.D., Mavrogenis A.F., Panagopoulos A.
    doi: 10.11138/ccmbm/2018.15.2.267
  25. Giant myxoid neurofibroma of the hip causing bone erosion: a case report
    Sacchetti F., De Gori M., D'Arienzo A., Grossi S., Cosseddu F., Capanna R.
    doi: 10.11138/ccmbm/2018.15.2.271
  26. Hypophosphatemic osteomalacia due to tenofovir-induced Fanconi syndrome in chronic hepatitis B patient
    Olmez Sarikaya N., Nas Kırdar N., Ates M.Y., Bilir I., Bayram K.B., Oruk G.
    doi: 10.11138/ccmbm/2018.15.2.276
  27. Efficacy and safety of locally injectable vitamin C on accelerating the orthodontic movement of maxillary canine impaction (oral mesotherapy technique): prospective study
    Yussif N.M., Dehis H.M., Rahman A.R.A.
    doi: 10.11138/ccmbm/2018.15.2.280
  28. Atypical lipomatous tumor: retrospective analysis, prognostic factors and MRI in differential diagnosis
    Muratori F., Roselli G., Bettini L., Frenos F., D'Arienzo A., Campanacci D.A., Mondanelli N., Matera D., Cuomo P., Scoccianti G., Beltrami G., Totti F., Capanna R.
    doi: 10.11138/ccmbm/2018.15.2.288
  29. Integral dental treatment in patient with osteoporosis secondary to hypothyroidism prior to therapy with bisphosphonate: case report and literature review
    Zuñiga Araya M.E., Herrera J.L.A., Martínez R.E.M., Delgado J.H.O., Garrigós Portales D.
    doi: 10.11138/ccmbm/2018.15.2.294
  30. A rare case of misdiagnosis: sacrococcygeal osteoid osteoma that was treated surgically as a pilonidal sinus in a pediatric patient
    Akif Çaçan M., Karaca S., Çakır A., Uçar B.Y.
    doi: 10.11138/ccmbm/2018.15.2.300
Last Viewed articles: la lista degli ultimi x visitati.
  1. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study
    Doria C., Tranquilli Leali P., Solla F., Maestretti G., Balsano M., Scarpa R.M.
    doi: 10.11138/ccmbm/2016.13.3.195
credits